Clinical Trials Logo

Infant, Very Low Birth Weight clinical trials

View clinical trials related to Infant, Very Low Birth Weight.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01809548 Active, not recruiting - Clinical trials for Infant, Very Low Birth Weight

Preterm Infants on Early Solid Foods

PIES-Project
Start date: October 2013
Phase: N/A
Study type: Interventional

Introduction: Preterm infants with a birth weight less than 1500 grams have special nutritional needs in comparison to full-term neonates. During their stay in the neonatal intensive care unit an increased supply with energy, protein and electrolytes is necessary to establish adequate growth. After discharge from the hospital special breast milk supplements or post discharge formulas are available to cover the special nutrient requirements. Complementary feeding in preterm infants is an unexplored field so far and nutritional concepts for the first year of life are not available. Data concerning the optimal time for starting solid foods are missing as well as information concerning the ideal composition of complementary food. In this context it is essential to meet the special nutritional needs of "Ex-Preemies" on the one hand and avoid overfeeding and later obesity on the other hand. So far it remains unclear, what the "safe" time point for introduction of solid food to premature infants is and whether this time point influences growth, body composition, neurodevelopmental outcome or the incidence of atopic disease.

NCT ID: NCT01353313 Active, not recruiting - Clinical trials for Bronchopulmonary Dysplasia

Hydrocortisone for BPD

Start date: August 11, 2011
Phase: Phase 3
Study type: Interventional

The Hydrocortisone and Extubation study will test the safety and efficacy of a 10 day course of hydrocortisone for infants who are less than 30 weeks estimated gestational age and who are intubated at 14-28 days of life. Infants will be randomized to receive hydrocortisone or placebo. This study will determine if hydrocortisone improves infants'survival without moderate or severe BPD and will be associated with improvement in survival without moderate or severe neurodevelopmental impairment at 22 - 26 months corrected age.